On May 28, 2025, Needham analyst Ami Fadia initiated coverage on Alkermes (ALKS, Financial) with a "Buy" rating. The investment firm set a price target of $45.00 USD for the stock. This action reflects a positive outlook for Alkermes, underscoring the potential for growth in the company's market valuation.
Alkermes (ALKS, Financial) is a biopharmaceutical company known for developing innovative medicines for the treatment of central nervous system (CNS) diseases. The initiation of coverage and the accompanying buy rating from Needham may influence investor sentiment and impact trading activity.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 13 analysts, the average target price for Alkermes PLC (ALKS, Financial) is $39.77 with a high estimate of $52.00 and a low estimate of $30.00. The average target implies an upside of 33.01% from the current price of $29.90. More detailed estimate data can be found on the Alkermes PLC (ALKS) Forecast page.
Based on the consensus recommendation from 15 brokerage firms, Alkermes PLC's (ALKS, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Alkermes PLC (ALKS, Financial) in one year is $26.97, suggesting a downside of 9.8% from the current price of $29.9. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Alkermes PLC (ALKS) Summary page.
